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Retinal dystrophies cause severe visual impairment due to
the death of photoreceptor and retinal pigment epithelium
cells. These diseases until recently have been considered
to be incurable. In the last two decades genetic studies
have shed light on the molecular causes of several of these
diseases, which has opened new avenues to develop thera-
peutic approaches. The mammalian eye has been at
the forefront of therapeutic trials based on gene augmen-
tation in humans with Leber congenital amaurosis, an
early-onset recessive retinal dystrophy, due to mutations
in the retinal pigment epithelium-specific protein 65 kDa
(RPE65) gene. Tremendous challenges still lie ahead to
extrapolate these studies to other retinal disease-causing
genes, as human gene augmentation studies require testing
in animal models for each individual gene and sufficiently
large patient cohorts for clinical trials remain to be identi-
fied through cost-effective mutation screening protocols.
Pharmacological approaches to antagonize retinal
degeneration are also under development, including mod-
ulation of the immune system.
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